Skip NavigationSkip to Content

Incidence and risk factors for tuberculosis at a rural HIV clinic in Uganda, 2012-2019; A retrospective cohort study

  1. Author:
    Sendagire, Ibrahim
    Ssempijja,Victor
    Ndyanabo, Anthony
    Ssettuba, Absalom
    Mawanda, Annie N
    Nakigozi, Gertrude
    Lukoye, Deus
    Fitzmaurice, Arthur G
    Muhindo, Richard
    Zawedde-Muyanja, Stella
    Reynolds, Steven J
  2. Author Address

    Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Kampala, Uganda. isendagire@rhsp.org., Rakai Health Sciences Program, Kalisizo, Kyotera, Uganda., Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Division of Global HIV & TB, Global Health Center, US Centers for Disease Control and Prevention, Kampala, Uganda., Department of Nursing, Makerere College of Health Sciences, Kampala, Uganda., Infectious Diseases Institute, Makerere College of Health Sciences, Kampala, Uganda., Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA., Johns Hopkins University School of Medicine, Baltimore, MD, USA.,
    1. Year: 2025
    2. Date: May 22
    3. Epub Date: 2025 05 22
  1. Journal: BMC Public Health
    1. 25
    2. 1
    3. Pages: 1882
  2. Type of Article: Article
  3. Article Number: 1882
  1. Abstract:

    Background: Tuberculosis (TB) is the leading cause of death among people living with HIV (PLHIV). Antiretroviral therapy (ART) initiation lowers the risk of HIV-associated TB. Earlier studies have shown TB incidence to be high in the first year of ART. We undertook a study to (1) assess the incidence of TB and (2) associated factors among persons initiating ART in a rural cohort. Methods: We conducted a retrospective cohort analysis study among PLHIV aged = 18 years, initiated on ART from January 1, 2012, to December 31, 2019, and TB disease-free at the time of ART initiation, at Kalisizo ART clinic. TB disease incidence was calculated by dividing the number of new TB cases by the total follow-up time expressed per 100 person-years among persons followed up until the date of incident TB disease, loss to follow-up, transfer out, death or censored at the end of the study; whichever occurred first. Factors associated with TB disease incidence were assessed in the multivariable analysis by Poisson regression analysis at 5% significance level. Results: For the period 2012 to 2019, 2,589 PLHIV were initiated on ART; 57% (1,470/2,589) were female. Females were more likely to be aged below 35 years while males were more likely to be aged 25-44 years (p < 0.001). Eighty-seven per cent (1,269/1,470) of females compared to 78% (866/1,119) of males were in WHO clinical stage 1 (p < 0.001). Sixty-one TB disease events were observed in 7,363 person-years. The overall TB disease incidence was 0.83 (95% CI: 0.63-1.06) per 100 person-years. Males were more likely than females to develop TB disease, adjusted incidence rate ratio (adj IRR) 2.13 (95% CI: 1.27-3.57) per 100 person-years, p = 0.004. Compared to using ART for 0-5 months, time on ART was associated with a lower TB incidence rate at 6-12 months, 13-24 months, > 24 months (adj IRR 0.20 (95% CI: 0.09-0.46), 0.14 (95% CI: 0.06-0.33), 0.16 (95% CI: 0.08-0.31) p < 0.001 respectively). Conclusions and recommendations: Incidence of TB among PLHIV on ART was low in this rural population. Clinicians offering care to people with HIV in the rural setting should have a heightened index of suspicion for TB disease. Keywords: Africa; TB; TB incidence during ART; TB/HIV prevalence; Tuberculosis; Tuberculosis in HIV patients; Tuberculosis in rural areas.

    See More

External Sources

  1. DOI: 10.1186/s12889-025-23090-8
  2. PMID: 40405106
  3. PII : 10.1186/s12889-025-23090-8

Library Notes

  1. Fiscal Year: FY2024-2025
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel